Novel paradigms for the gut–brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder
Frontiers in Psychiatry · 29.09.2023 · 14
DOI: 10.3389/fpsyt.2023.1203362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 29.09.2023. Verfasst von Vatsalya Vatsalya und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville, Louisville, KY, United States. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, NIGMS NIH HHS, Intramural NIH HHS.
Themen: Sucht und Abhängigkeit, Depression
Abstract (Originalsprache)
Introduction
Patients with alcohol use disorder (AUD) exhibit symptoms such as alcohol withdrawal, depression, and cravings. The gut-immune response may play a significant role in manifesting these specific symptoms associated with AUD. This study examined the role of gut dysfunction, proinflammatory cytokines, and hormones in characterizing AUD symptoms.
Methods
Forty-eight AUD patients [men ( n = 34) and women ( n = 14)] aged 23–63 years were grouped using the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA) as clinically significant (CS-CIWA [score > 10] [ n = 22]) and a clinically not-significant group (NCS-CIWA [score ≤ 10] [ n = 26]). Clinical data (CIWA, 90-day timeline followback [TLFB90], and lifetime drinking history [LTDH]) and blood samples (for testing proinflammatory cytokines, hormones, and markers of intestinal permeability) were analyzed. A subset of 16 AUD patients was assessed upon admission for their craving tendencies related to drug-seeking behavior using the Penn-Alcohol Craving Score (PACS).
Results
CS-CIWA group patients exhibited unique and significantly higher levels of adiponectin and interleukin (IL)-6 compared to NCS-CIWA. In the CS group, there were significant and high effects of association for the withdrawal score with gut-immune markers (lipopolysaccharide [LPS], adiponectin, IL-6, and IL-8) and for withdrawal-associated depression with gut-immune markers (scored using MADRS with LPS, soluble cells of differentiation type 14 [sCD14], IL-6, and IL-8). Craving (assessed by PACS, the Penn-Alcohol Craving Scale) was significantly characterized by what could be described as gut dysregulation (LBP [lipopolysaccharide binding protein] and leptin) and candidate proinflammatory (IL-1β and TNF-α) markers. Such a pathway model describes the heavy drinking phenotype, HDD90 (heavy drinking days past 90 days), with even higher effects (R 2 = 0.955, p = 0.006) in the AUD patients, who had higher ratings for cravings (PACS > 5).
Discussion
The interaction of gut dysfunction cytokines involved in both inflammation and mediating activity constitutes a novel pathophysiological gut–brain axis for withdrawal symptoms and withdrawal-associated depression and craving symptoms in AUD. AUD patients with reported cravings show a significant characterization of the gut–brain axis response to heavy drinking.
Trial registration
ClinicalTrials.gov , identifier: NCT# 00106106.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville, Louisville, KY, United States.
- Robley Rex VA Medical Center, Louisville, KY, United States.
- National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, United States.
- Clincial Laboratory for the Intervention Development of AUD and Organ Severity, Louisville, KY, United States.
- Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, Netherlands.
- Centre for Human Psychopharmacology, Swinburne University, Melbourne, VIC, Australia.
Förderung
- NIAAA NIH HHS
- NIGMS NIH HHS
- Intramural NIH HHS
- NCI NIH HHS
Zitieren
APA
Vatsalya, V., Verster, J. C., Sagaram, M., Royer, A. J., Hu, H., Parthasarathy, R., Schwandt, M. L., Kong, M., Ramchandani, V. A., Feng, W., Agrawal, R., Zhang, X., & McClain, C. J. (2023). Novel paradigms for the gut–brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1203362
Vancouver
Vatsalya V, Verster JC, Sagaram M, Royer AJ, Hu H, Parthasarathy R, et al. Novel paradigms for the gut–brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder. Frontiers in Psychiatry. 2023;14. doi:10.3389/fpsyt.2023.1203362
BibTeX
@article{Vatsalya2023,
author = {Vatsalya, Vatsalya and Verster, Joris C and Sagaram, Manasa and Royer, Amor J and Hu, Huirong and Parthasarathy, Ranganathan and Schwandt, Melanie L and Kong, Maiying and Ramchandani, Vijay A and Feng, Wenke and Agrawal, Ruchita and Zhang, Xiang and McClain, Craig J},
title = {Novel paradigms for the gut–brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder},
journal = {Frontiers in Psychiatry},
year = {2023},
volume = {14},
doi = {10.3389/fpsyt.2023.1203362}
}
EUVIMED